USA flag logo/image

An Official Website of the United States Government

THE OVERALL OBJECTIVE OF THIS RESEARCH IS TO EVALUATE THE POTENTIAL EFFICACY OF…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
4771
Program Year/Program:
1986 / SBIR
Agency Tracking Number:
4771
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Piedmont Research Company
3508 University Dr Suite #2 Durham, NC 27707
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1986
Title: THE OVERALL OBJECTIVE OF THIS RESEARCH IS TO EVALUATE THE POTENTIAL EFFICACY OF HORMONOCONJUGATE THERAPY FOR MELANOMA.
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THE OVERALL OBJECTIVE OF THIS RESEARCH IS TO EVALUATE THE POTENTIAL EFFICACY OF HORMONOCONJUGATE THERAPY FOR MELANOMA.RESEARCHERS WILL CONJUGATE SEVERAL DIFFERENT PROTEINS OR OR PEPTIDES TO THE HORMONE MSH AND ATTEMPT TO DELIVER THESE TO MURINE B16 MELANOMA. THE GOAL IS TO USE MSH AS A VEHICLEFOR DELIVERING AN IMMUNOGENIC MOLECULE TO THE B16 CELL MEMBRANE, THEREBY PROVIDING A TARGET FOR IMMUNE DESTRUCTION OF THE TUMOR CELLS. TO ACCOMPLISH THIS, THE CONJUGATES WILLBE SYNTHESIZED AND THEIR ACTIVITY EXAMINED IN VITRO. CONJUGATES THAT RETAIN RECEPTOR BINDING ACTIVITY WILL NEXT BE EVALUATED FOR THEIR IMMUNOGENICITY AND FOR THEIR ABILITY TO LOCALIZE TO B16 CELLS IN VIVO. FINALLY, APPROPRIATE CONJUGATES WILL BE USED FOR IN SITU MANIPULATION OF THE IMMUNOGENICITY OF B16 CELLS. SATISFACTORY COMPLETION OF THIS RESEARCH SHOULD LEAD INTO THE DEVELOPMENT OF SINGLE- AGENT THERAPY FOR MELANOMA.

Principal Investigator:

Gary m stuhlmiller
PRINCIPAL INVESTIGATOR
9199680433

Business Contact:

Small Business Information at Submission:

Piedmont Research Company
3508 University Drive Suite 2 Durham, NC 27707

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No